反应详情

To a solution of 1-tert-butyl-5-(1-methyl-4-{4-[3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca1(14),2,4,10,12-pentaen-12-yl}-1H-pyrazol-5-yl)-λ3,3-oxazocan-2-one (540 mg, 0.94 mmol) in MeOH (10 mL) was added 4N HCl (2 mL). The reaction mixture was stirred at room temperature for 4 h. 1N K2CO3 (6.0 mL) was added. After concentration, the residue was purified by reverse phase Combiflash eluting with a 0-70% gradient of CH3CN in 0.3% NH4HCO3 to afford 4-[3-methyl-1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-12-[1-methyl-5-(piperidin-3-yl)-1H-pyrazol-4-yl]-9-oxa-3,6-diazatricyclo[8.4.0.02,6]tetradeca1(14),2,4,10,12-pentaene (320 mg, 72% yield). LCMS (ESI) m/z: 473.4 [M+H+]

1. concentrationAfter concentration
2. customthe residue was purified by reverse phase Combiflash
3. washeluting with a 0-70% gradient of CH3CN in 0.3% NH4HCO3